A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension
Objectives: Statins by their anti-inflammatory and endothelial stabilizing effect can be beneficial in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH). The present study was done to evaluate the effect of rosuvastatin on pulmonary functions and quality of l...
Gespeichert in:
| Veröffentlicht in: | Indian journal of pharmacology 2016-09, Vol.48 (5), p.503-508 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 508 |
|---|---|
| container_issue | 5 |
| container_start_page | 503 |
| container_title | Indian journal of pharmacology |
| container_volume | 48 |
| creator | Chogtu, Bharti Kuriachan, Sanitha Magazine, Rahul Shetty, K Kamath, Asha George, Manu Tripathy, Amruta Kumar, D |
| description | Objectives: Statins by their anti-inflammatory and endothelial stabilizing effect can be beneficial in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH). The present study was done to evaluate the effect of rosuvastatin on pulmonary functions and quality of life (QOL) in patients with concomitant COPD and PH.
Materials and Methods: It was a prospective, randomized, double-blind, placebo-controlled, study conducted in patients with COPD and PH. A total of sixty patients were assigned to receive either rosuvastatin 10 mg or placebo once a day in addition to their conventional treatment for 12 weeks. Routine blood investigations, pulmonary functions, echocardiogram, exercise capacity, and QOL using a questionnaire were assessed at the baseline and after 12 weeks.
Results: In patients of rosuvastatin group, there was a statistically significant increase in peak expiratory flow rate (PEFR) (P = 0.04) but no significant change in other pulmonary functions: Forced vital capacity (FVC), forced expiratory volume at 1 s (FVC, FEV 1 , FEV 1 /FVC), and echocardiogram parameters. There was a significant increase in 6-min walk test (6-min walk distance) (P = 0.03) at the end of 12 weeks. On comparing with placebo, rosuvastatin showed a significant reduction (P = 0.045) in COPD exacerbations while adverse effects did not differ.
Conclusion: Statins have a favorable effect on patients with COPD and PH regarding the improvement in PEFR, COPD exacerbations, and exercise capacity. Such effects can be beneficial in these patients and more so in patients with concomitant coronary artery disease or hyperlipidemia where long-term benefits of statins have been established. |
| doi_str_mv | 10.4103/0253-7613.190721 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5051242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A464132161</galeid><sourcerecordid>A464132161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c590t-1e8ff5dc11942e81ed0f7b9d387d69a35f0262c748bbe753c9c0652d84a732c13</originalsourceid><addsrcrecordid>eNptkk2P0zAQhiMEYsvCnROyxIUDKXYc54MDUrUsH9JKXOBsuc6k9W5iB9tpVf4Kf5YJ3S0tqhIptueZd8aTN0leMjrPGeXvaCZ4WhaMz1lNy4w9SmasrquUl4I9TmaH8EXyLIRbivu8Lp4mF1mJsOD5LPm9IIN3YQAdzQbeEq9s43rzCxoS4tjs3pPrjepGFY2zxLUkroFA2yI-7TBz3KgQMWwJvgMuwMZAtiauiV57Z40mbhmiH_8WIMPY9c4qvyONCaACECx4dLreDeAj2ID1nidPWtUFeHH_vUx-fLr-fvUlvfn2-evV4ibVoqYxZVC1rWg0Y3WeQcWgoW25rBtelU1RKy5amhWZLvNquYRScF1rWoisqXJV8kwzfpl82OsO47KHRuMNvOrk4E2PLUmnjDyNWLOWK7eRggqW5RkKvLkX8O7nCCHK3gQNXacsuDFIVnGR04KJCX39H3rrRm_xekgVlNasLPJ_1Ep1II1tHdbVk6hc5EXOeMaKqe_0DLUCC9iks9AaPD7h52d4fBrojT6bQPcJGn908NAeZsKonAwoJ4fJyWFyb0BMeXU8y0PCg-MQ-LgHtq6L4MNdN27BS2TvrNueCKdHwjhrLhfywav8D2DP7nA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1860091764</pqid></control><display><type>article</type><title>A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Chogtu, Bharti ; Kuriachan, Sanitha ; Magazine, Rahul ; Shetty, K ; Kamath, Asha ; George, Manu ; Tripathy, Amruta ; Kumar, D</creator><creatorcontrib>Chogtu, Bharti ; Kuriachan, Sanitha ; Magazine, Rahul ; Shetty, K ; Kamath, Asha ; George, Manu ; Tripathy, Amruta ; Kumar, D</creatorcontrib><description>Objectives: Statins by their anti-inflammatory and endothelial stabilizing effect can be beneficial in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH). The present study was done to evaluate the effect of rosuvastatin on pulmonary functions and quality of life (QOL) in patients with concomitant COPD and PH.
Materials and Methods: It was a prospective, randomized, double-blind, placebo-controlled, study conducted in patients with COPD and PH. A total of sixty patients were assigned to receive either rosuvastatin 10 mg or placebo once a day in addition to their conventional treatment for 12 weeks. Routine blood investigations, pulmonary functions, echocardiogram, exercise capacity, and QOL using a questionnaire were assessed at the baseline and after 12 weeks.
Results: In patients of rosuvastatin group, there was a statistically significant increase in peak expiratory flow rate (PEFR) (P = 0.04) but no significant change in other pulmonary functions: Forced vital capacity (FVC), forced expiratory volume at 1 s (FVC, FEV 1 , FEV 1 /FVC), and echocardiogram parameters. There was a significant increase in 6-min walk test (6-min walk distance) (P = 0.03) at the end of 12 weeks. On comparing with placebo, rosuvastatin showed a significant reduction (P = 0.045) in COPD exacerbations while adverse effects did not differ.
Conclusion: Statins have a favorable effect on patients with COPD and PH regarding the improvement in PEFR, COPD exacerbations, and exercise capacity. Such effects can be beneficial in these patients and more so in patients with concomitant coronary artery disease or hyperlipidemia where long-term benefits of statins have been established.</description><identifier>ISSN: 0253-7613</identifier><identifier>EISSN: 1998-3751</identifier><identifier>DOI: 10.4103/0253-7613.190721</identifier><identifier>PMID: 27721534</identifier><language>eng</language><publisher>India: Wolters Kluwer - Medknow Publications</publisher><subject>Aged ; Anti-Inflammatory Agents - therapeutic use ; Chronic obstructive lung disease ; Chronic obstructive pulmonary disease ; Double-Blind Method ; Drug therapy ; Echocardiography - drug effects ; Female ; Forced Expiratory Volume - drug effects ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypertension ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - physiopathology ; Male ; Middle Aged ; Patient outcomes ; Peak Expiratory Flow Rate - drug effects ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - physiopathology ; Pulmonary hypertension ; Quality of Life ; Rosuvastatin ; Rosuvastatin Calcium - therapeutic use ; Statins ; Studies ; Treatment Outcome ; Vital Capacity - drug effects ; Walking</subject><ispartof>Indian journal of pharmacology, 2016-09, Vol.48 (5), p.503-508</ispartof><rights>COPYRIGHT 2016 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt Ltd Sep/Oct 2016</rights><rights>Copyright: © 2016 Indian Journal of Pharmacology 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c590t-1e8ff5dc11942e81ed0f7b9d387d69a35f0262c748bbe753c9c0652d84a732c13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051242/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051242/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27721534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chogtu, Bharti</creatorcontrib><creatorcontrib>Kuriachan, Sanitha</creatorcontrib><creatorcontrib>Magazine, Rahul</creatorcontrib><creatorcontrib>Shetty, K</creatorcontrib><creatorcontrib>Kamath, Asha</creatorcontrib><creatorcontrib>George, Manu</creatorcontrib><creatorcontrib>Tripathy, Amruta</creatorcontrib><creatorcontrib>Kumar, D</creatorcontrib><title>A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension</title><title>Indian journal of pharmacology</title><addtitle>Indian J Pharmacol</addtitle><description>Objectives: Statins by their anti-inflammatory and endothelial stabilizing effect can be beneficial in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH). The present study was done to evaluate the effect of rosuvastatin on pulmonary functions and quality of life (QOL) in patients with concomitant COPD and PH.
Materials and Methods: It was a prospective, randomized, double-blind, placebo-controlled, study conducted in patients with COPD and PH. A total of sixty patients were assigned to receive either rosuvastatin 10 mg or placebo once a day in addition to their conventional treatment for 12 weeks. Routine blood investigations, pulmonary functions, echocardiogram, exercise capacity, and QOL using a questionnaire were assessed at the baseline and after 12 weeks.
Results: In patients of rosuvastatin group, there was a statistically significant increase in peak expiratory flow rate (PEFR) (P = 0.04) but no significant change in other pulmonary functions: Forced vital capacity (FVC), forced expiratory volume at 1 s (FVC, FEV 1 , FEV 1 /FVC), and echocardiogram parameters. There was a significant increase in 6-min walk test (6-min walk distance) (P = 0.03) at the end of 12 weeks. On comparing with placebo, rosuvastatin showed a significant reduction (P = 0.045) in COPD exacerbations while adverse effects did not differ.
Conclusion: Statins have a favorable effect on patients with COPD and PH regarding the improvement in PEFR, COPD exacerbations, and exercise capacity. Such effects can be beneficial in these patients and more so in patients with concomitant coronary artery disease or hyperlipidemia where long-term benefits of statins have been established.</description><subject>Aged</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Chronic obstructive lung disease</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Echocardiography - drug effects</subject><subject>Female</subject><subject>Forced Expiratory Volume - drug effects</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypertension</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Hypertension, Pulmonary - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient outcomes</subject><subject>Peak Expiratory Flow Rate - drug effects</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - physiopathology</subject><subject>Pulmonary hypertension</subject><subject>Quality of Life</subject><subject>Rosuvastatin</subject><subject>Rosuvastatin Calcium - therapeutic use</subject><subject>Statins</subject><subject>Studies</subject><subject>Treatment Outcome</subject><subject>Vital Capacity - drug effects</subject><subject>Walking</subject><issn>0253-7613</issn><issn>1998-3751</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk2P0zAQhiMEYsvCnROyxIUDKXYc54MDUrUsH9JKXOBsuc6k9W5iB9tpVf4Kf5YJ3S0tqhIptueZd8aTN0leMjrPGeXvaCZ4WhaMz1lNy4w9SmasrquUl4I9TmaH8EXyLIRbivu8Lp4mF1mJsOD5LPm9IIN3YQAdzQbeEq9s43rzCxoS4tjs3pPrjepGFY2zxLUkroFA2yI-7TBz3KgQMWwJvgMuwMZAtiauiV57Z40mbhmiH_8WIMPY9c4qvyONCaACECx4dLreDeAj2ID1nidPWtUFeHH_vUx-fLr-fvUlvfn2-evV4ibVoqYxZVC1rWg0Y3WeQcWgoW25rBtelU1RKy5amhWZLvNquYRScF1rWoisqXJV8kwzfpl82OsO47KHRuMNvOrk4E2PLUmnjDyNWLOWK7eRggqW5RkKvLkX8O7nCCHK3gQNXacsuDFIVnGR04KJCX39H3rrRm_xekgVlNasLPJ_1Ep1II1tHdbVk6hc5EXOeMaKqe_0DLUCC9iks9AaPD7h52d4fBrojT6bQPcJGn908NAeZsKonAwoJ4fJyWFyb0BMeXU8y0PCg-MQ-LgHtq6L4MNdN27BS2TvrNueCKdHwjhrLhfywav8D2DP7nA</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Chogtu, Bharti</creator><creator>Kuriachan, Sanitha</creator><creator>Magazine, Rahul</creator><creator>Shetty, K</creator><creator>Kamath, Asha</creator><creator>George, Manu</creator><creator>Tripathy, Amruta</creator><creator>Kumar, D</creator><general>Wolters Kluwer - Medknow Publications</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160901</creationdate><title>A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension</title><author>Chogtu, Bharti ; Kuriachan, Sanitha ; Magazine, Rahul ; Shetty, K ; Kamath, Asha ; George, Manu ; Tripathy, Amruta ; Kumar, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c590t-1e8ff5dc11942e81ed0f7b9d387d69a35f0262c748bbe753c9c0652d84a732c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Chronic obstructive lung disease</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Echocardiography - drug effects</topic><topic>Female</topic><topic>Forced Expiratory Volume - drug effects</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypertension</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Hypertension, Pulmonary - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient outcomes</topic><topic>Peak Expiratory Flow Rate - drug effects</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - physiopathology</topic><topic>Pulmonary hypertension</topic><topic>Quality of Life</topic><topic>Rosuvastatin</topic><topic>Rosuvastatin Calcium - therapeutic use</topic><topic>Statins</topic><topic>Studies</topic><topic>Treatment Outcome</topic><topic>Vital Capacity - drug effects</topic><topic>Walking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chogtu, Bharti</creatorcontrib><creatorcontrib>Kuriachan, Sanitha</creatorcontrib><creatorcontrib>Magazine, Rahul</creatorcontrib><creatorcontrib>Shetty, K</creatorcontrib><creatorcontrib>Kamath, Asha</creatorcontrib><creatorcontrib>George, Manu</creatorcontrib><creatorcontrib>Tripathy, Amruta</creatorcontrib><creatorcontrib>Kumar, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Indian journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chogtu, Bharti</au><au>Kuriachan, Sanitha</au><au>Magazine, Rahul</au><au>Shetty, K</au><au>Kamath, Asha</au><au>George, Manu</au><au>Tripathy, Amruta</au><au>Kumar, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension</atitle><jtitle>Indian journal of pharmacology</jtitle><addtitle>Indian J Pharmacol</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>48</volume><issue>5</issue><spage>503</spage><epage>508</epage><pages>503-508</pages><issn>0253-7613</issn><eissn>1998-3751</eissn><abstract>Objectives: Statins by their anti-inflammatory and endothelial stabilizing effect can be beneficial in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH). The present study was done to evaluate the effect of rosuvastatin on pulmonary functions and quality of life (QOL) in patients with concomitant COPD and PH.
Materials and Methods: It was a prospective, randomized, double-blind, placebo-controlled, study conducted in patients with COPD and PH. A total of sixty patients were assigned to receive either rosuvastatin 10 mg or placebo once a day in addition to their conventional treatment for 12 weeks. Routine blood investigations, pulmonary functions, echocardiogram, exercise capacity, and QOL using a questionnaire were assessed at the baseline and after 12 weeks.
Results: In patients of rosuvastatin group, there was a statistically significant increase in peak expiratory flow rate (PEFR) (P = 0.04) but no significant change in other pulmonary functions: Forced vital capacity (FVC), forced expiratory volume at 1 s (FVC, FEV 1 , FEV 1 /FVC), and echocardiogram parameters. There was a significant increase in 6-min walk test (6-min walk distance) (P = 0.03) at the end of 12 weeks. On comparing with placebo, rosuvastatin showed a significant reduction (P = 0.045) in COPD exacerbations while adverse effects did not differ.
Conclusion: Statins have a favorable effect on patients with COPD and PH regarding the improvement in PEFR, COPD exacerbations, and exercise capacity. Such effects can be beneficial in these patients and more so in patients with concomitant coronary artery disease or hyperlipidemia where long-term benefits of statins have been established.</abstract><cop>India</cop><pub>Wolters Kluwer - Medknow Publications</pub><pmid>27721534</pmid><doi>10.4103/0253-7613.190721</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0253-7613 |
| ispartof | Indian journal of pharmacology, 2016-09, Vol.48 (5), p.503-508 |
| issn | 0253-7613 1998-3751 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5051242 |
| source | MEDLINE; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Aged Anti-Inflammatory Agents - therapeutic use Chronic obstructive lung disease Chronic obstructive pulmonary disease Double-Blind Method Drug therapy Echocardiography - drug effects Female Forced Expiratory Volume - drug effects Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypertension Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - physiopathology Male Middle Aged Patient outcomes Peak Expiratory Flow Rate - drug effects Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - physiopathology Pulmonary hypertension Quality of Life Rosuvastatin Rosuvastatin Calcium - therapeutic use Statins Studies Treatment Outcome Vital Capacity - drug effects Walking |
| title | A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T19%3A51%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective,%20randomized%20study:%20Evaluation%20of%20the%20effect%20of%20rosuvastatin%20in%20patients%20with%20chronic%20obstructive%20pulmonary%20disease%20and%20pulmonary%20hypertension&rft.jtitle=Indian%20journal%20of%20pharmacology&rft.au=Chogtu,%20Bharti&rft.date=2016-09-01&rft.volume=48&rft.issue=5&rft.spage=503&rft.epage=508&rft.pages=503-508&rft.issn=0253-7613&rft.eissn=1998-3751&rft_id=info:doi/10.4103/0253-7613.190721&rft_dat=%3Cgale_pubme%3EA464132161%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1860091764&rft_id=info:pmid/27721534&rft_galeid=A464132161&rfr_iscdi=true |